MAO-A/HSP90 dual inhibitors have the potential to reduce tumor immune evasion and act as immune checkpoint inhibitors as they limited IFN-γ-induced PD-L1 expression in glioblastoma cells. This evidence concerns the gene MAOA and glioblastoma.